CTOs on the Move


 
Arzeda The Protein Design Company is a synthetic biology company.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Arzeda raised $12M on 07/20/2017

Similar Companies

Verona Pharma

Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

The THOR Group

The THOR Group is a Manhattan Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.

OpenTrons

We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other`s results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century`s most important questions.

ImmunoPrecise Antibodies

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.